Bouet G, Mookerjee S, Foster H, Waller A, Ghevaert C
Mines Saint-Étienne, université Lyon, université Jean-Monnet, Inserm, U 1059 Sainbiose, Centre CIS, Saint-Étienne, France.
Wellcome trust-medical research council Cambridge Stem Cell Institute and department of haematology, university of Cambridge, CB2 0PT Cambridge, UK.
Bull Acad Natl Med. 2020 Dec;204(9):981-988. doi: 10.1016/j.banm.2020.10.004. Epub 2020 Oct 13.
Platelet transfusions, which are currently totally dependent on altruistic donations, are absolutely necessary to the treatment of patients with thrombocytopenia following trauma, surgery or other pathologies (especially malignancies). Producing platelets in vitro represent a major technological and scientific breathrough that would address logistical issues (supply chain, stock holding…) and medical concerns (compatibility and biosafety). The translation of this innovation will need to be accompanied by rigorous quality control, harmonised between laboratory when it comes to functionality and biosafety for use in the clinic.
目前完全依赖于利他性捐赠的血小板输注,对于治疗创伤、手术或其他病症(尤其是恶性肿瘤)后出现血小板减少症的患者来说绝对必要。体外生产血小板代表了一项重大的技术和科学突破,这将解决后勤问题(供应链、库存管理等)以及医学问题(兼容性和生物安全性)。这项创新的转化需要严格的质量控制,在实验室之间就临床使用的功能和生物安全性进行协调统一。